Cognition Therapeutics Stock Price on November 27, 2024
| CGTX Stock | USD 0.40 0.01 2.44% |
If you're considering investing in Cognition Stock, it is important to understand the factors that can impact its price. As of today, the current price of Cognition Therapeutics stands at 0.40, as last reported on the 30th of November, with the highest price reaching 0.40 and the lowest price hitting 0.38 during the day. Cognition Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0845, which signifies that the company had a -0.0845% return per unit of risk over the last 3 months. Cognition Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cognition Therapeutics' Risk Adjusted Performance of (0.07), standard deviation of 6.29, and Mean Deviation of 4.27 to double-check the risk estimate we provide.
At this time, Cognition Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Stock Based Compensation is likely to rise to about 4.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 27.5 M in 2024. . At this time, Cognition Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price Earnings To Growth Ratio is likely to rise to 0.0007 in 2024, despite the fact that Price Earnings Ratio is likely to grow to (2.04). Cognition Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Cognition |
Sharpe Ratio = -0.0845
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CGTX |
Estimated Market Risk
| 6.29 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cognition Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cognition Therapeutics by adding Cognition Therapeutics to a well-diversified portfolio.
Price Book 1.1416 | Book Value 0.761 | Enterprise Value -4.9 M | Enterprise Value Ebitda (0.44) | Shares Float 33.9 M |
Related Headline
Tscan Therapeutics Headline on 27th of November 2024
TScan Therapeutics, Inc. Shares Bought by Brown Brothers Har... by thelincolnianonline.com
Brown Brothers Harriman Co. raised its position in TScan Therapeutics, Inc. by 88.2 percent in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,051 shares of the companys stock after buying an additional 67,027 shares during the period. Brown Brothers Harriman
Cognition Therapeutics Valuation on November 27, 2024
It is possible to determine the worth of Cognition Therapeutics on a given historical date. On November 27, 2024 Cognition was worth 0.41 at the beginning of the trading date compared to the closed value of 0.4. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cognition Therapeutics stock. Still, in general, we apply an absolute valuation method to find Cognition Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cognition Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cognition Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 0.39 | 0.41 | 0.38 | 0.40 | 7,019,654 | |
11/27/2024 | 0.41 | 0.41 | 0.38 | 0.40 | 1,896,882 |
| 0.40 | 0.40 | 0.38 | 0.40 | 866,243 |
| Backtest Cognition Therapeutics | | | Cognition Therapeutics History | | | Cognition Therapeutics Valuation | Previous | Next |
Cognition Therapeutics Trading Date Momentum on November 27, 2024
| On November 29 2024 Cognition Therapeutics was traded for 0.40 at the closing time. The top price for the day was 0.40 and the lowest listed price was 0.38 . The trading volume for the day was 866.2 K. The trading history from November 29, 2024 did not affect price variability. The overall trading delta against the current closing price is 0.00% . |
Cognition Therapeutics Fundamentals Correlations and Trends
By evaluating Cognition Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cognition financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Cognition Therapeutics Stock history
Cognition Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cognition is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cognition Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cognition Therapeutics stock prices may prove useful in developing a viable investing in Cognition Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 30 M | 27.5 M | |
| Net Loss | -19.3 M | -20.2 M |
Cognition Therapeutics Quarterly Net Working Capital |
|
Cognition Therapeutics Stock Technical Analysis
Cognition Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Cognition Therapeutics Period Price Range
Low | November 30, 2024
| High |
0.00 | 0.00 |
Cognition Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Cognition Therapeutics November 30, 2024 Market Strength
Market strength indicators help investors to evaluate how Cognition Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cognition Therapeutics shares will generate the highest return on investment. By undertsting and applying Cognition Therapeutics stock market strength indicators, traders can identify Cognition Therapeutics entry and exit signals to maximize returns
Cognition Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cognition Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Cognition Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cognition to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.83) | |||
| Total Risk Alpha | (1.69) | |||
| Treynor Ratio | (0.45) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.